# Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

> **NCT02977468** · PHASE1 · RECRUITING · sponsor: **Eileen Connolly** · enrollment: 15 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Merck 3475 Pembrolizumab
- **RADIATION:** Intraoperative radiation therapy (IORT)

## Key facts

- **NCT ID:** NCT02977468
- **Lead sponsor:** Eileen Connolly
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-10-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977468, "Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02977468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*